AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25389489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral education program
Number of subjects: 90
Study 25389489 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education program
Number of subjects: 90
Study 25389489 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-intervention)
Number of subjects: 90
Study 22675288 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic Index (GI) change
Number of subjects: 756
Study 22675288 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic Load (GL) change
Number of subjects: 756
Study 19683152 — intervention group
Group type: EXPERIMENTAL
Intervention: Biaxial microincision cataract surgery with UltraChoice 1.0 Rollable Thinlens intraocular lens (IOL)
Number of subjects: 150
Study 19683152 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 150
Study 19683152 — intervention group
Group type: EXPERIMENTAL
Intervention: Biaxial microincision cataract surgery with UltraChoice 1.0 Rollable Thinlens IOL
Number of subjects: 150
Study 17575467 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day) + Pioglitazone (30 mg/day)
Number of subjects: 60
Study 17575467 — intervention group
Group type: COMPARATOR
Intervention: Losartan (100 mg/day)
Number of subjects: 60
Study 15236135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic cuff technique
Number of subjects: 81
Study 15236135 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 81
Study 15236135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined application of Valsalva maneuver and pneumatic cuff techniques
Number of subjects: 81
Study 12660264 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH (1200 IU)
Number of subjects: 25
Study 12660264 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (5000 IU)
Number of subjects: 25
Study 12660264 — intervention group
Group type: COMPARATOR
Intervention: Control (stimulation test 1)
Number of subjects: 25
Study 10589951 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 14
Study 10589951 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA
Number of subjects: 14
Study 10589951 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 8961475 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg) in addition to ondansetron (8 mg three times a day)
Number of subjects: 104
Study 8961475 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to ondansetron (8 mg three times a day)
Number of subjects: 104
Study 1742515 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 150 mg
Number of subjects: 108
Study 1742515 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 mg
Number of subjects: 108
Study 7342331 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 25 mg per kg body weight bid for one day (Group III)
Number of subjects: 97
Study 7342331 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 25 mg per kg body weight in a single dose (Group IV)
Number of subjects: 97
Study 7342331 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg per kg body weight in a single dose (Group V)
Number of subjects: 97
Study 7342331 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild and transient side effects (all groups)
Number of subjects: 97
Study 7342331 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical improvement (all groups)
Number of subjects: 97
Study 30623548 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week comprehensive exercise training
Number of subjects: 136
Study 30623548 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 28877108 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel protector
Number of subjects: 54
Study 28877108 — intervention group
Group type: COMPARATOR
Intervention: Standard care (pillows)
Number of subjects: 54
Study 26761398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy sessions analysis
Number of subjects: 35
Study 25086427 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control feedback (KR feedback for half of their trials whenever they wanted)
Number of subjects: 22
Study 25086427 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-control feedback (KR feedback after half of both their good and bad trials)
Number of subjects: 22
Study 25086427 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback for any trials)
Number of subjects: 22
Study 22630801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) therapy (12 sessions of computer-assisted CR)
Number of subjects: 41
Study 22630801 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 41
Study 22630801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) therapy
Number of subjects: 41
Study 19649678 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk index based on 39 risk factors including age, gender, BMI, perceived health, and various health conditions.
Number of subjects: 24115
Study 17848424 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 4000
Study 15710812 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline-assisted LASEK (HS-LASEK)
Number of subjects: 52
Study 15710812 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-assisted LASEK (A-LASEK)
Number of subjects: 52
Study 12523867 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 100 mg/week
Number of subjects: 16
Study 12523867 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 200 mg/week
Number of subjects: 16
Study 12523867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9155505 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (SeMet) 200 micrograms daily
Number of subjects: 36
Study 9155505 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenate (Se-enriched yeast) 200 micrograms daily
Number of subjects: 36
Study 9155505 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no added Se)
Number of subjects: 36
Study 8102542 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 70
Study 8102542 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 70
Study 3612550 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (5-100 micrograms/kg)
Number of subjects: 12
Study 3612550 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (0.4 mg/kg)
Number of subjects: 12
Study 3612550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3612550 — intervention group
Group type: COMPARATOR
Intervention: Atropine, Phentolamine, Propranolol
Number of subjects: 12
Study 31723064 — intervention group
Group type: EXPERIMENTAL
Intervention: Etokimab
Number of subjects: 20
Study 31723064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29243443 — intervention group
Group type: EXPERIMENTAL
Intervention: CC+Gn+Dingkun Dan
Number of subjects: 60
Study 29243443 — intervention group
Group type: COMPARATOR
Intervention: CC+Gn+HCG
Number of subjects: 60
Study 27611776 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV)
Number of subjects: 209
Study 25205409 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided single-injection femoral nerve block with 40 ml of 0.5% bupivacaine and 1:200,000 epinephrine (Group F)
Number of subjects: 104
Study 25205409 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free saline (Group P)
Number of subjects: 104
Study 23060723 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular laser photocoagulation following intravitreal injection of triamcinolone acetonide (IVTA)
Number of subjects: 74
Study 23060723 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal injection of triamcinolone acetonide (IVTA) alone
Number of subjects: 74
Study 20214324 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial gout granules (SGGs)
Number of subjects: 60
Study 20214324 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium dual release enteric-coated capsules and Benzbromarone (Control)
Number of subjects: 60
Study 17855709 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI) at baseline
Number of subjects: 286
Study 17855709 — intervention group
Group type: COMPARATOR
Intervention: Lower body mass index (BMI) at baseline
Number of subjects: 286
Study 14985171 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-neutrophil conjugate formation induced by thrombin receptor activating peptide (TRAP)
Number of subjects: 30
Study 14985171 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin I levels
Number of subjects: 30
Study 14985171 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet aggregation (induced by ADP and arachidonic acid)
Number of subjects: 30
Study 14985171 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 30
Study 14985171 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAP-induced platelet-neutrophil conjugate formation
Number of subjects: 30
Study 14985171 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-neutrophil conjugates
Number of subjects: 30
Study 11434167 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with IgA nephropathy (IgA)
Number of subjects: 21
Study 11434167 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with Schönlein-Henoch purpura (Sch-H)
Number of subjects: 21
Study 11434167 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 healthy children)
Number of subjects: 21
Study 9596049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychiatric community care (IPCC) at general medical and surgical sites
Number of subjects: 271
Study 9596049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychiatric community care (IPCC) at neuropsychiatric sites
Number of subjects: 271
Study 9596049 — intervention group
Group type: COMPARATOR
Intervention: Standard Department of Veterans Affairs care at general medical and surgical sites
Number of subjects: 271
Study 9596049 — intervention group
Group type: COMPARATOR
Intervention: Standard Department of Veterans Affairs care at neuropsychiatric sites
Number of subjects: 271
Study 7512299 — intervention group
Group type: COMPARATOR
Intervention: Three TUHT treatments
Number of subjects: 28
Study 7512299 — intervention group
Group type: EXPERIMENTAL
Intervention: Six TUHT treatments
Number of subjects: 28
Study 2905803 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 0
Study 2905803 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (5 or 10 mg)
Number of subjects: 0
Study 2905803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2905803 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic BZ users
Number of subjects: 0
Study 2905803 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated anxious subjects
Number of subjects: 0
Study 1320621 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mm intramedullary rod (polyglycolide implants)
Number of subjects: 0
Study 1320621 — intervention group
Group type: COMPARATOR
Intervention: Kirschner wire
Number of subjects: 0
Study 82735 — intervention group
Group type: EXPERIMENTAL
Intervention: Enkephalin analogue [D‐Ala2, MePhe4, Met(o)‐ol] enkephalin (DAMME) administered intravenously
Number of subjects: 0
Study 82735 — intervention group
Group type: COMPARATOR
Intervention: Prior administration of the opiate antagonist, naloxone
Number of subjects: 0
Study 31014112 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative message emphasizing external factors while acknowledging personal responsibility
Number of subjects: 5007
Study 31014112 — intervention group
Group type: COMPARATOR
Intervention: Magnitude of problem message (comparison group 1)
Number of subjects: 5007
Study 31014112 — intervention group
Group type: COMPARATOR
Intervention: Magnitude of problem and inoculation messages (comparison group 2)
Number of subjects: 5007
Study 31014112 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter message emphasizing personal responsibility
Number of subjects: 5007
Study 31203241 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat (starting dose 75 mg/day, titrated 4-weekly)
Number of subjects: 300
Study 31203241 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa (control)
Number of subjects: 300
Study 28261923 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behaviour therapy (iCBT)
Number of subjects: 65
Study 28261923 — intervention group
Group type: COMPARATOR
Intervention: Monitored waitlist control
Number of subjects: 65
Study 26209233 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 gauge vitrectomy, endolaser, and gas tamponade (Group 1)
Number of subjects: 16
Study 26209233 — intervention group
Group type: COMPARATOR
Intervention: 23 gauge vitrectomy alone (Group 2)
Number of subjects: 16
Study 23250189 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE plus clinical immersion (RCT 1: 1 week SLE before 3 weeks clinical immersion)
Number of subjects: 349
Study 23250189 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE plus clinical immersion (RCT 2: 2 weeks interspersed SLE/clinical immersion)
Number of subjects: 349
Study 23250189 — intervention group
Group type: COMPARATOR
Intervention: Clinical immersion (control group)
Number of subjects: 349
Study 21303403 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic amoxicillin (AMX) 500mg + metronidazole (MET) 250mg, t.i.d. for 10 days
Number of subjects: 31
Study 21303403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 19246731 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-TPOm
Number of subjects: 0
Study 19246731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17122107 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg lutein
Number of subjects: 45
Study 17122107 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg lutein
Number of subjects: 45
Study 17122107 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lutein
Number of subjects: 45
Study 17122107 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of lutein
Number of subjects: 45
Study 15086634 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls Prevention Programme
Number of subjects: 0
Study 15086634 — intervention group
Group type: COMPARATOR
Intervention: Control graphs
Number of subjects: 0
Study 11401883 — intervention group
Group type: EXPERIMENTAL
Intervention: CNEP (‐5 cm H(2)O)
Number of subjects: 7
Study 11401883 — intervention group
Group type: EXPERIMENTAL
Intervention: NPV
Number of subjects: 7
Study 11401883 — intervention group
Group type: EXPERIMENTAL
Intervention: NPV plus NEEP
Number of subjects: 7
Study 11401883 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB)
Number of subjects: 7
Study 9203079 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestimulus EEG microstate (oriented left anterior-right posterior)
Number of subjects: 12
Study 9203079 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestimulus EEG microstate (right anterior-left posterior)
Number of subjects: 12
Study 9203079 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stimulus ERP microstates
Number of subjects: 12
Study 8352217 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T vaccine
Number of subjects: 484
Study 8352217 — intervention group
Group type: COMPARATOR
Intervention: HbOC vaccine
Number of subjects: 484
Study 2962529 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol 2.5 g orally
Number of subjects: 207
Study 2962529 — intervention group
Group type: COMPARATOR
Intervention: Spectinomycin 2 g intramuscularly
Number of subjects: 207
Study 31265205 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperception spinal cord stimulation (SCS) at ≤1.2 kHz
Number of subjects: 140
Study 31265205 — intervention group
Group type: COMPARATOR
Intervention: Supraperception spinal cord stimulation (SCS)
Number of subjects: 140
Study 31265205 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperception spinal cord stimulation (SCS) at 12 months post-activation
Number of subjects: 140
Study 31265205 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple waveform options
Number of subjects: 140
Study 30124744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance assessment
Number of subjects: 96
Study 30124744 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional capacity (FC) assessment
Number of subjects: 96
Study 30124744 — intervention group
Group type: COMPARATOR
Intervention: Clinical symptoms assessment
Number of subjects: 96
Study 30124744 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported disability assessment
Number of subjects: 96
Study 28406862 — intervention group
Group type: EXPERIMENTAL
Intervention: IV hydrocortisone
Number of subjects: 49
Study 28406862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 25604154 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 20
Study 25604154 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBOT)
Number of subjects: 20
Study 24094979 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus cognitive-behavioral therapy (STD + CBT)
Number of subjects: 101
Study 24094979 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative care (STD)
Number of subjects: 101
Study 21602025 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle‐sparing group (modified Watson‐Jones approach)
Number of subjects: 102
Study 21602025 — intervention group
Group type: COMPARATOR
Intervention: Mini‐incision direct lateral group (control)
Number of subjects: 102
Study 18430857 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 95
Study 18430857 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy population)
Number of subjects: 95
Study 18430857 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment
Number of subjects: 95
Study 18430857 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable Alzheimer's disease
Number of subjects: 95
Study 18430857 — intervention group
Group type: EXPERIMENTAL
Intervention: Possible Alzheimer's disease
Number of subjects: 95
Study 16517051 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD0947 (25mg/day for 12 weeks)
Number of subjects: 0
Study 16517051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12243656 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cc of 2% intrarectal lidocaine gel (Xylocaine 2% jelly, Astra Pharma Inc.) 5 to 10 minutes before the procedure
Number of subjects: 360
Study 12243656 — intervention group
Group type: COMPARATOR
Intervention: 10 cc of lubricating gel
Number of subjects: 360
Study 10652641 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist
Number of subjects: 0
Study 10652641 — intervention group
Group type: COMPARATOR
Intervention: TNFα blockade
Number of subjects: 0
Study 7593073 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance venography
Number of subjects: 45
Study 7593073 — intervention group
Group type: COMPARATOR
Intervention: Contrast venography
Number of subjects: 45
Study 2305099 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of contrast material injected at the level of the external iliac artery (EIA)
Number of subjects: 52
Study 2305099 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL of contrast material injected at the level of the EIA
Number of subjects: 52
Study 2305099 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mL of contrast material injected at the level of the aortic bifurcation and 60 mL injected at the level of the EIA
Number of subjects: 52
Study 2305099 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL injected at the level of the EIA with inflow occlusion
Number of subjects: 52
Study 2305099 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL injected at the level of the EIA without inflow occlusion
Number of subjects: 52
Study 7005123 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (80 mg)
Number of subjects: 7
Study 7005123 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide + Triamterene (80 + 100 mg)
Number of subjects: 7
Study 7005123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 28338504 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective group (tidal volume; 6 mL/kg predicted body weight, 6 cm H2O positive end-expiratory pressure with recruitment maneuvers)
Number of subjects: 78
Study 28338504 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (10 mL/kg predicted body weight, no positive end-expiratory pressure)
Number of subjects: 78
Study 28338504 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective group
Number of subjects: 78
Study 28338504 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 78
Study 26657997 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mcg unadjuvanted clade 2 vaccine
Number of subjects: 177
Study 26657997 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-mcg unadjuvanted clade 2 vaccine
Number of subjects: 177
Study 26657997 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-mcg dosage in unprimed recipients
Number of subjects: 177
Study 26657997 — intervention group
Group type: EXPERIMENTAL
Intervention: Clade 1 stimulation
Number of subjects: 177
Study 26657997 — intervention group
Group type: EXPERIMENTAL
Intervention: Clade 2 stimulation
Number of subjects: 177
Study 26657997 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted clade 1 H5N1 vaccines
Number of subjects: 177
Study 26657997 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted clade 1 H5N1 vaccines
Number of subjects: 177
Study 24651512 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercises (STRE)
Number of subjects: 80
Study 24651512 — intervention group
Group type: COMPARATOR
Intervention: Flexibility exercises (FLEX)
Number of subjects: 80
Study 24651512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (STRE and FLEX)
Number of subjects: 80
Study 24651512 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercises (STRE) and Flexibility exercises (FLEX)
Number of subjects: 80